SCHEMBL1662724

SCHEMBL1662724

COc1ccc(N2CCN(C(=O)OCC(C)C)CC2=O)c(F)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPS1 P31327 2/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.42
MTNR1B P49286 1/20 0.42
P2RX7 Q99572 6/20 0.41
GPR119 Q8TDV5 1/20 0.40
ROCK2 O75116 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR2A P28223 1/20 0.38
SCN9A Q15858 1/20 0.37
SCN10A Q9Y5Y9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662961 0.87 P2RX7 (0.42) PTGDR2P2RX7GPR119L3MBTL1MAPT
SCHEMBL1663380 0.84 PTGDR2 (0.44) PTGDR2P2RX7GPR119MAPTALDH1A1
SCHEMBL1583489 0.84 SCN9A (0.51) PTGDR2P2RX7MAPTALDH1A1LMNA
SCHEMBL1662800 0.82 PTGDR2 (0.44) PTGDR2P2RX7MAPTALDH1A1LMNA
SCHEMBL1584703 0.82 CPS1 (0.46) CPS1P2RX7GPR119MAPTALDH1A1
SCHEMBL1663277 0.80 PTGDR2 (0.49) PTGDR2ROCK2ALDH1A1LMNAHPGD
SCHEMBL1583770 0.78 HRH3 (0.45) PTGDR2ROCK2L3MBTL1ALDH1A1HPGD
SCHEMBL1583807 0.77 HRH3 (0.42) PTGDR2P2RX7LMNACYP3A4
SCHEMBL1583535 0.77 HRH3 (0.49) P2RX7CYP3A4
SCHEMBL1583729 0.77 PTGDR2 (0.39) PTGDR2P2RX7MAPTALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011050284-A1 PYRAZOLYLPYRIDINE ANTIVIRAL AGENTS GLAXOSMITHKLINE LLC (US) 2011-04-28 WO disclosed